Crinetics Pharmaceuticals Inc (CRNX) Stock Price, Quote & News

Company Profile

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant,...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 450 6464

Website: www.crinetics.com

Address:

6055 Lusk Boulevard, San Diego, United States

CH_Expat Mar. 12 at 2:36 PM

$CRNX Added at 35.60 USD.

0 · Reply

CH_Expat Mar. 6 at 7:32 PM

$CRNX This is starting to get really interesting at this price. Acromegaly indication alone will bring at least 1b in peak sales. CAH, cushing and especially NET are really looking promising. EV of 1.5b or less is where I will start to go really deep here. Furthermore, I still see $NVO go for them.

1 · Reply

CH_Expat Mar. 5 at 6:36 PM

$CRNX Added a bit.

0 · Reply

ZManicItalian Mar. 4 at 8:37 PM

$CRNX in buy zone.

0 · Reply

CH_Expat Mar. 4 at 6:50 PM

$CRNX Really glad to be back. Did a lot of DD today. If IDYA does what it should and this is still in this price range, my profits will partially come here.

1 · Reply

SannieVerraderlijk Mar. 3 at 3:00 PM

$NUVB $CYTK $CRNX Took some starters amidst this carnage, added $ABVX

0 · Reply

CalledThis1 Mar. 2 at 8:45 PM

$CRNX nibbled

0 · Reply

CH_Expat Mar. 2 at 4:34 PM

$CRNX Your favorite German is back.

1 · Reply

CH_Expat Mar. 2 at 3:08 PM

$CRNX @CDMO You wait?

1 · Reply

BillionerOfKing Mar. 2 at 2:32 PM

$CRNX Current Stock Price: $41.43 Contracts to trade: $42.0 CRNX Mar 20 2026 Call Entry: $4.59 Exit: $7.29 ROI: 59% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2025 Earnings Call Transcript

Feb 26, 2026, 4:05 PM EST - 17 days ago

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 5, 2026, 4:05 PM EST - 5 weeks ago

Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March

Jan 26, 2026, 5:00 PM EST - 6 weeks ago

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Jan 22, 2026, 4:05 PM EST - 7 weeks ago

Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)

Jan 13, 2026, 3:56 PM EST - 2 months ago

Crinetics Pharmaceuticals, Inc. (CRNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 4:05 PM EST - 2 months ago

Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 6, 2026, 9:22 PM EST - 2 months ago

Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Jan 5, 2026, 4:02 PM EST - 2 months ago

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

Jan 5, 2026, 1:27 PM EST - 2 months ago

Crinetics Pharmaceuticals, Inc. (CRNX) Discusses PALSONIFY Launch Progress and Phase 2 Atumelnant Results in Congenital Adrenal Hyperplasia Transcript

Jan 5, 2026, 8:00 AM EST - 2 months ago

Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia

Jan 4, 2026, 4:00 PM EST - 2 months ago

Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia

Dec 18, 2025, 4:05 PM EST - 3 months ago

Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference

Dec 11, 2025, 4:05 PM EST - 3 months ago

Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

Dec 10, 2025, 4:34 PM EST - 3 months ago

Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 3, 2025, 8:00 AM EST - 3 months ago

Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors

Nov 20, 2025, 4:05 PM EST - 4 months ago

Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome

Nov 10, 2025, 4:28 PM EST - 4 months ago

Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 7, 2025, 12:46 PM EST - 4 months ago

Crinetics Pharmaceuticals, Inc. (CRNX) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:05 PM EST - 4 months ago

Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 23, 2025, 8:00 AM EDT - 5 months ago

Crinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting

Oct 10, 2025, 4:41 PM EDT - 5 months ago

Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 6, 2025, 4:05 PM EDT - 5 months ago

Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

Sep 26, 2025, 5:00 PM EDT - 6 months ago

Crinetics: FDA Approval And Expansion Of Palsonify In Focus, Maintaining 'Buy' Rating

Sep 26, 2025, 1:57 AM EDT - 6 months ago

Crinetics Pharmaceuticals, Inc. - Special Call

Sep 25, 2025, 5:30 PM EDT - 6 months ago

Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly

Sep 10, 2025, 4:30 PM EDT - 6 months ago

Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 21, 2025, 8:45 AM EDT - 7 months ago

Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH)

Aug 11, 2025, 4:05 PM EDT - 7 months ago

Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 9, 2025, 11:21 AM EDT - 7 months ago

Crinetics Pharmaceuticals, Inc. (CRNX) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 7 months ago

Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 13, 2025, 5:45 PM EDT - 8 months ago

Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025

Jul 11, 2025, 8:00 AM EDT - 8 months ago

Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 10, 2025, 4:28 PM EDT - 8 months ago

Crinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 30, 2025, 4:05 PM EDT - 9 months ago

Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline

Jun 16, 2025, 8:00 AM EDT - 9 months ago

Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025

Jun 10, 2025, 4:29 PM EDT - 9 months ago

Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 23, 2025, 8:00 AM EDT - 10 months ago

Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025

May 15, 2025, 4:05 PM EDT - 10 months ago

Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025

May 12, 2025, 4:05 PM EDT - 10 months ago

Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 10, 2025, 1:50 PM EDT - 11 months ago

Crinetics Pharmaceuticals, Inc (CRNX) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:05 PM EDT - 11 months ago

Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 11, 2025, 8:00 AM EDT - 1 year ago

Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 10, 2025, 5:04 PM EDT - 1 year ago

Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 2, 2025, 2:15 PM EDT - 1 year ago

Crinetics Pharma: Strong Progress With Multiple Indications And Upcoming PDUFA

Mar 27, 2025, 4:05 PM EDT - 1 year ago

Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly

Mar 10, 2025, 4:36 PM EDT - 1 year ago

Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 28, 2025, 1:01 PM EST - 1 year ago

Crinetics Pharmaceuticals, Inc (CRNX) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:05 PM EST - 1 year ago

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 24, 2025, 8:30 AM EST - 1 year ago

Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer

CH_Expat Mar. 12 at 2:36 PM

$CRNX Added at 35.60 USD.

0 · Reply

CH_Expat Mar. 6 at 7:32 PM

1 · Reply

CH_Expat Mar. 5 at 6:36 PM

$CRNX Added a bit.

0 · Reply

ZManicItalian Mar. 4 at 8:37 PM

$CRNX in buy zone.

0 · Reply

CH_Expat Mar. 4 at 6:50 PM

$CRNX Really glad to be back. Did a lot of DD today. If IDYA does what it should and this is still in this price range, my profits will partially come here.

1 · Reply

SannieVerraderlijk Mar. 3 at 3:00 PM

$NUVB $CYTK $CRNX Took some starters amidst this carnage, added $ABVX

0 · Reply

CalledThis1 Mar. 2 at 8:45 PM

$CRNX nibbled

0 · Reply

CH_Expat Mar. 2 at 4:34 PM

$CRNX Your favorite German is back.

1 · Reply

CH_Expat Mar. 2 at 3:08 PM

$CRNX @CDMO You wait?

1 · Reply

BillionerOfKing Mar. 2 at 2:32 PM

0 · Reply

Quantumup Mar. 2 at 11:42 AM

Citizens⬇️ $CRNX to $96 from $105 and reiterated at Market Outperform $AZN $IPSEY $NBIX $NVS PFE Here's what Citizens had to say in its note to investors: https://x.com/Quantumup1/status/2028434518785282074?s=20

1 · Reply

CH_Expat Feb. 27 at 4:54 PM

$CRNX A little more and I will be back.

0 · Reply

Walleyeslayer Feb. 27 at 4:18 PM

$CRNX 40 is a critical level here. 👀

0 · Reply

Trainguy1 Feb. 27 at 2:42 PM

$CRNX @S_Franconi I noticed on the CHMP's Feb 2026 plenary highlights document that CRNX's Palsonify was recommended for EMA approval.

1 · Reply

StocktwitsEarnings Feb. 26 at 9:36 PM

$CRNX Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$1.29 down -46.59% YoY • Reported revenue of $6.16M • Crinetics Pharmaceuticals expects product revenue to increase with PALSONIFY's commercialization, but anticipates continued net losses in the near term as operating expenses are projected to rise with ongoing investments.

0 · Reply

StocktwitsEarnings Feb. 26 at 9:36 PM

$CRNX Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$1.29 down -46.59% YoY • Reported revenue of $6.16M • Crinetics Pharmaceuticals expects product revenue to increase with expanding commercialization efforts for PALSONIFY, but anticipates continued net losses in the near term due to increased operating expenses and R&D investments.

0 · Reply

NettyLite Feb. 26 at 6:55 PM

$CRNX does anyone give a shit about this stock but me? Getting nervous. Earnings today? Bueller

1 · Reply

OfficialStocktwitsUser Feb. 22 at 11:36 PM

$CRNX RSI: 30.21, MACD: -1.9820 Vol: 3.59, MA20: 47.56, MA50: 49.32 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

CapitalRadiance Feb. 20 at 2:12 PM

$CRNX Crinetics Pharmaceuticals develops endocrine disorder therapies. Clinical execution drives valuation. Cash runway supports development.

0 · Reply

NettyLite Feb. 18 at 10:40 AM

$CRNX a very special robot friend told me to buy this

0 · Reply

CH_Expat Feb. 18 at 9:49 AM

$CRNX Baker Bros bought in heavily here as per their latest filing!

0 · Reply

SpectralWick Feb. 18 at 9:03 AM

$CRNX Specialty pharma with binary trial risk; valuation resets quickly after regulatory milestones.

0 · Reply

Market Cap	3.93B
Revenue (ttm)	7.70M
Net Income (ttm)	-465.32M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-6,043.12%
Debt to Equity Ratio	0.00

Volume	956,500
Avg Vol	1,247,696
Day's Range	N/A - N/A
Shares Out	104.71M
Stochastic %K	38%
Beta	0.23
Analysts	Strong Sell
Price Target	$83.50